MARROW HYPERPLASIA

This adverse event was reported 682 times

MARROW HYPERPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ISATUXIMAB-IRFC 1 0.0185
1 DICLOFENAC SODIUM/MISOPROSTOL 3 0.0068
2 TOLMETIN SODIUM 1 0.0059
3 PENICILLIN G POTASSIUM 4 0.0055
4 POTASSIUM PHOSPHATE, MONOBASIC AND SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS 1 0.0055
5 PENICILLIN G 11 0.0047
6 DIMETICONE 1 0.0035
7 1169 HYDROGEN PEROXIDE SPRAY 1 0.0032
8 HYDROGEN PEROXIDE 1 0.0030
9 DEFEROXAMINE MESYLATE 5 0.0023
See all drugs enriched for association with MARROW HYPERPLASIA

MARROW HYPERPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Actinomycin [EPC] 4 0.0018
1 Thrombopoietin Receptor Agonist [EPC] 25 0.0016
2 Erythroid Maturation Agent [EPC] 3 0.0011
3 Lipid-based Polyene Antifungal [EPC] 12 0.0009
4 Isocitrate Dehydrogenase 1 Inhibitor [EPC] 2 0.0009
5 Benzothiazole [EPC] 2 0.0009
6 Sulfone [EPC] 9 0.0008
7 CD33-directed Immunoconjugate [EPC] 3 0.0008
8 Antimalarial [EPC] 8 0.0008
9 Antiprotozoal [EPC] 8 0.0008
See all drug classes enriched for association with MARROW HYPERPLASIA